Neuromuscular Disorders

In Multiple Sclerosis, Anxiety May Signal Depression

In Multiple Sclerosis, Anxiety May Signal Depression

By

A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.

Meditation May Benefit Anxiety, Depression in Amyotrophic Lateral Sclerosis

Meditation May Benefit Anxiety, Depression in Amyotrophic Lateral Sclerosis

By

Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.

RENEW Trial: Promising Results for Optic Neuritis Treatment

RENEW Trial: Promising Results for Optic Neuritis Treatment

By

Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.

FDA Approves Duchenne Muscular Dystrophy Drug

FDA Approves Duchenne Muscular Dystrophy Drug

By

Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

By

Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

By

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

MicroRNA in Multiple Sclerosis May Signify Disease Progression

MicroRNA in Multiple Sclerosis May Signify Disease Progression

By

Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

By

Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

By

Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

By

Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.

Alexion Seeking New Indication for Myasthenia Gravis Drug

Alexion Seeking New Indication for Myasthenia Gravis Drug

By

Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Template Improves Quality of Report on MRI for Multiple Sclerosis

Template Improves Quality of Report on MRI for Multiple Sclerosis

By

More structured MRI reports may aid in the diagnosis of multiple sclerosis.

Potential Prognostic Biomarker for Clinically Isolated Syndrome

Potential Prognostic Biomarker for Clinically Isolated Syndrome

By

It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.

FDA Approves First Treatment for Spinal Muscular Atrophy

FDA Approves First Treatment for Spinal Muscular Atrophy

By

The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.

ACE Inhibitors May Help Slow Myocardial Fibrosis In Muscular Dystrophy

ACE Inhibitors May Help Slow Myocardial Fibrosis In Muscular Dystrophy

By

Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.

Low Neonatal Vitamin D May Increase Risk of MS

Low Neonatal Vitamin D May Increase Risk of MS

By

Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.

New Drug for Spinal Muscular Atrophy Shows Promise

New Drug for Spinal Muscular Atrophy Shows Promise

Despite the benefits observed, the improvements still do not represent normal muscle function.

Surgery May Boost Risk of Guillain-Barré in Immuno-Compromised

Surgery May Boost Risk of Guillain-Barré in Immuno-Compromised

Patients with cancer or an autoimmune disease who underwent surgery were at a greater risk.

Rituximab Offers Hope for Refractory Myasthenia Gravis

Rituximab Offers Hope for Refractory Myasthenia Gravis

By

Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

By

Previous MRI studies focused on gray matter changes only.

A Good Diet Translates into Better Functionality in ALS

A Good Diet Translates into Better Functionality in ALS

By

The foods most negatively correlated with ALSFRS-R score were milk, lunchmeats, and beef and pork.

Alemtuzumab May Reduce Disability in Early MS

Alemtuzumab May Reduce Disability in Early MS

By

The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.

Does Exercise Influence Risk of Multiple Sclerosis?

Does Exercise Influence Risk of Multiple Sclerosis?

By

Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.

Eteplirsen Earns Accelerated Approval for Duchenne Muscular Dystrophy

Eteplirsen Earns Accelerated Approval for Duchenne Muscular Dystrophy

By

Eteplirsen is the first drug approved in the US for the treatment of DMD.

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

By

Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

By

Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.

Smoking May Accelerate White Matter Damage in Progressive MS

Smoking May Accelerate White Matter Damage in Progressive MS

By

The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.

Enriching Experiences May Protect Against Cognitive Decline in MS

Enriching Experiences May Protect Against Cognitive Decline in MS

By

Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.

High-Fat Diets May Increase Relapse Risk in Pediatric MS

High-Fat Diets May Increase Relapse Risk in Pediatric MS

By

High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.

Sign Up for Free e-newsletters